By Bill Farnum | Executive Director
Hello everyone, hope you are having a great Summer!
We are really looking forward to a great year in 2012 with respect to helping fund critical research projects for Rett Syndrome. All of our 2012 Casting 4 A Cure events are currently sold out and we are at maximum capacity! Great news as this should really help us hit our fiscal goals this year of donating $100,000 to the International Rett Syndrome Foundation. So far this year we have donated $30,000 to the International Rett Syndrome Foundation.
We will concentrate our efforts on funding the 1st phase of the clinical trials for the drug NNZ-2566 (http://www.rettsyndrome.org/content/view/848/1147/) which are being held in conjunction with Children's Hospital in Houston. Neuren Pharmaceuticals has joined with the Baylor College of Medicine to test NNZ-2566 in a proposed Phase I and Phase IIa clinical trial. This proposed trial, along with the IGF-1 trial at the Children’s Hospital in Boston, are trials designed to investigate whether these compounds can reverse some of the symptoms of Rett syndrome and modify the progression of the disorder in our Rett children. This announcement portrays the importance of partnerships between industry, academia, and private foundations like IRSF to accelerate bringing forward clinical trials specific to Rett syndrome.
Thank you again for your support!
Bill
Links:
By Bill Farnum | Executive Director
By Bill Farnum | Executive Director
Project reports on GlobalGiving are posted directly to globalgiving.org by Project Leaders as they are completed, generally every 3-4 months. To protect the integrity of these documents, GlobalGiving does not alter them; therefore you may find some language or formatting issues.
If you donate to this project or have donated to this project, you can receive an email when this project posts a report. You can also subscribe for reports without donating.
